Abstract 4587
Background
Despite the accumulation of knowledge on the cognitive side-effects of chemotherapy, the actual incidence of this impairment is still a subject of research. Estimates of affected patients vary from 17% to 78% across studies.In recent years, growing attention is being paid to the potential adverse effects of chemotherapy on brain and cognitive function. Despite the accumulation of knowledge on the cognitive side-effects of chemotherapy, the actual incidence of this impairment is still a subject of research. Estimates of affected patients vary from 17% to 78% across studies. The aim of the study is to evaluate cognitive function changes experienced by cancer patients who receive chemotherapy and associated factors.
Methods
This is a descriptive study. The data collection phase of the study is ongoing and the results obtained from 47 patients who received chemotherapy have been reported here. The results of the large group will be presented at the congress. Data collection was started on March 2019 and will be continuing until September 2019. This study was conducted in a Research and Training Hospital in Istanbul/Turkey. Data were collected by using the Patient İnformation form and Functional Assessment of Chronic Illness Therapy- Cognitive Function (FACIT-Cog) and The European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30). Mann-Whitney U test, Kruskal-Wallis test, and Spearman Correlation analysis were used to evaluate the data.
Results
There was statistically significant and positive relationship between FACIT-Cog “perceived cognitive impairments” subscale and EORTC-30 cognitive (r = 0,755; p ≤ 0,001), emotional (r = 0,505; p = 0,001) and social (r = 0,504; p = 0,001) functioning subscales. There was statistically significant and positive relationship between FACIT-Cog “comments from others on cognitive function” and EORTC-30 emotional (r = 0,491; p = 0,001), cognitive (r = 0,539; p ≤ 0,001), and social (r = 0,588; p ≤ 0,001) functioning subscales. FACIT-Cog scores was not significantly differ by patients’ characteristics (p > 0,005).
Conclusions
Cognitive function should be assessed and considered during the care of cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4506 - Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity
Presenter: Adel Samson
Session: Poster Display session 3
Resources:
Abstract
1631 - Randomized phase 2 clinical trial of NY-ESO-1 protein vaccine combined with cholesteryl pullulan (CHP-NY-ESO-1) in resected esophageal cancer patients
Presenter: Shinichi Kageyama
Session: Poster Display session 3
Resources:
Abstract
4244 - T cell repertoire sequencing reveals dynamics of response to dendritic cell vaccine plus dasatinib for checkpoint blockade resistant metastatic melanoma
Presenter: Luca Quagliata
Session: Poster Display session 3
Resources:
Abstract
5791 - Ixovex, a novel oncolytic E1B-mutated adenovirus
Presenter: Mohiemen Anwar
Session: Poster Display session 3
Resources:
Abstract
4170 - Anti-CSPG4 DNA vaccination as a promising strategy for the treatment of CSPG4+ tumors: a comparative oncology trial
Presenter: Federica Riccardo
Session: Poster Display session 3
Resources:
Abstract
5780 - Antitumor activity, immunogenicity and safety of a novel PD-1 vaccine in combination with two chimeric HER-2 peptide vaccine in syngeneic Balb/c, C57Bl/6 models and in beagle dogs
Presenter: Pravin Kaumaya
Session: Poster Display session 3
Resources:
Abstract
5860 - Maternal immunization against ALK as a weapon to fight neuroblastoma
Presenter: Giuseppina Barutello
Session: Poster Display session 3
Resources:
Abstract
4720 - Phase 1 study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific, in patients (pts) with advanced solid tumors
Presenter: Jason Luke
Session: Poster Display session 3
Resources:
Abstract
5717 - Anti-PD-L1/IL-15 fusion protein generates robust adaptive immune gene signatures in tumors leading to tumor inhibition and memory responses
Presenter: Stella Martomo
Session: Poster Display session 3
Resources:
Abstract
1802 - Evaluation of the anti-tumor efficacy and immune effects of N-809, a novel IL-15 superagonist/anti-PD-L1 bispecific agent
Presenter: Kristin Hicks
Session: Poster Display session 3
Resources:
Abstract